Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial

References

• Sasaki K, Higashihara M, Inoue K, Igarashi Y, Makino S. Studies on the development of a live attenuated mumps virus vaccine. Kitasato Arch Exp Med. 1976;49:43–52.
   PubMedGoogle Scholar
• Rubin SA. Mumps vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 7th ed. Philadelphia (PA): Elsevier; 2018. p. 663–88.
   Google Scholar
• Nakayama T. Vaccine chronicles in Japan. J Infect Chemother. 2013;19:787–98. doi:10.1007/s10156-013-0641-6.
   PubMed Web of Science ®Google Scholar
• Ueda K, Miyazaki C, Hidaka Y, Okada K, Kusuhara K, Kadoya R. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet. 1995;346:701–02. doi:10.1016/S0140-6736(95)92311-X.
   PubMed Web of Science ®Google Scholar
• Makino S, Sasaki K, Nakayama T, Oka S, Urano T, Kimura M, Kawana R, Yamamura AM. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. Am J Dis Child. 1990;144:905–10.
   PubMedGoogle Scholar
• Nagai T, Okafuji T, Miyazaki C, Ito Y, Kamada M, Kumagai T, Yuri K, Sakiyama H, Miyata A, Ihara T, et al. A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine. 2007;25:2742–47. doi:10.1016/j.vaccine.2005.11.068.
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Fujioka M, Kinumaki H, Kinki Ambulatory Pediatrics Study Group. An office-based prospective study of deafness in mumps. Pediatr Infect Dis J. 2009;28:173–75. doi:10.1097/INF.0b013e31818a8ca8.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Commentary: is Japan deaf to mumps vaccination? Pediatr Infect Dis J. 2009;28:176. doi:10.1097/INF.0b013e31818a8cc6.
   PubMed Web of Science ®Google Scholar
• National Institute of Infectious Diseases. Mumps (infectious parotitis) in Japan, as of September 2016. IASR. 2016;37:185–86.
   Google Scholar
• Sawada A, Yamaji Y, Nakayama T. Mumps Hoshino and Torii vaccine strains were distinguished from circulating wild strains. J Infect Chemother. 2013;19:480–85. doi:10.1007/s10156-012-0515-3.
   PubMed Web of Science ®Google Scholar
• Jin L, Örvell C, Myers R, Rota PA, Nakayama T, Forcic D, Hiebert J, Brown KE. Genomic diversity of mumps virus and global distribution of the 12 genotypes. Rev Med Virol. 2015;25(2):85–101. doi:10.1002/rmv.1819.
   PubMed Web of Science ®Google Scholar
• Inou Y, Nakayama T, Yoshida N, Uejima H, Yuri K, Kamada M, Kumagai T, Sakiyama H, Miyata A, Ochiai H, et al. Molecular epidemiology of mumps virus in Japan and proposal of two new genotypes. J Med Virol. 2004;73:97–104. doi:10.1002/jmv.20065.
   PubMed Web of Science ®Google Scholar
• Kuba Y, Kyan H, Arakaki E, Takara T, Kato T, Okano S, Oshiro Y, Kudaka J, Kidokoro M. Molecular epidemiological study of mumps epidemics of 2015 in Okinawa, Japan. Jpn J Infect Dis. 2017;70(3):329–32. doi:10.7883/yoken.JJID.2016.390.
   PubMed Web of Science ®Google Scholar
• Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine. 1. Vaccine development. Proc Soc Exp Biol Med. 1966;123:768–75. doi:10.3181/00379727-123-31599.
   PubMed Web of Science ®Google Scholar
• Takla A, Bohmer MM, Klinc C, Kurz N, Schaffer A, Stich H, Stocker P, Wichmann O, Kach J. Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Hum Vaccin Immunother. 2014;10(1):140–45. doi:10.4161/hv.26642.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Hill Schwartz JM, Hunt K, Finley CG, Leschinsky DP, O’Keefe AL, et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008;358(15):1580–89. doi:10.1056/NEJMoa0706589.
   PubMed Web of Science ®Google Scholar
• Tillieux SL, Halsey WS, Sathe GM, Vssilev V. Comparative analysis of the complete nucleotide sequences of measles, mumps, and rubella strain genomes contained in Priorix-TetraTM and ProQuadTM live attenuated combined vaccines. Vaccine. 2009;27:2265–73. doi:10.1016/j.vaccine.2009.01.112.
   PubMed Web of Science ®Google Scholar
• Wellington K, Goa KL. Measles, mumps, rubella vaccine (PriorixTM; GSK-MMR) A review of its use in the prevention of measles, mumps, and rubella. Drugs. 2003;63:2107–26. doi:10.2165/00003495-200363190-00012.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Onoda K. Vaccine adverse events reported in port-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine. 2007;25:570–76. doi:10.1016/j.vaccine.2006.05.130.
   PubMed Web of Science ®Google Scholar
• Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012;15(2):CD004407. doi:10.1002/14651858.CD004407.pub3.
   Google Scholar
• Rubin SA, Qi L, Audet SA, Sullivan B, Carbone KM, Bellini WJ, Rota PA, Sirota L, Beeler J. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008;198:508–15. doi:10.1086/590115.
   PubMed Web of Science ®Google Scholar
• Gouma S, Ten Hulscher HI, Schurink-van ‘T Klooster TM, de Melker HE, Boland GJ, Kaaijk P, van Els CACM, Koopmans MPG, van Binnendijk RS. Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection. Vaccine. 2016;34(35):4166–71. doi:10.1016/j.vaccine.2016.06.063.
   PubMed Web of Science ®Google Scholar
• Zengel J, Phan SI, Pickar A, Xu P, He B. Immunogenicity of mumps virus vaccine candidates matching circulating genotypes in the United States and China. Vaccine. 2017;35(32):3988–94. doi:10.1016/j.vaccine.2017.05.084.
   PubMed Web of Science ®Google Scholar
• Ennis FA. Immunity to mumps in an institutional epidemic: correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibition antibodies. J Infect Dis. 1969;119:654–57. doi:10.1093/infdis/119.6.654.
   PubMed Web of Science ®Google Scholar
• Latner DR, McGrew M, Williams NJ, Sowers SB, Bellini WJ, Hickman CJ. Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method. Clin Vaccine Immunol. 2014;21:286–97. doi:10.1128/CVI.00621-13.
   PubMed Web of Science ®Google Scholar
• Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, et al. Safety and immunogenicity of human serum albumin-free MMR vaccine in US children aged 12–15 months. J Pediatric Infect Dis Soc. 2015;4:339–48. doi:10.1093/jpids/piu081.
   PubMed Web of Science ®Google Scholar
• Schlipköter U, Mühlberger N, von Kries R, Weil J. Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany. Infection. 2002;30(6):351–55. doi:10.1007/s15010-002-3027-8.
   PubMed Web of Science ®Google Scholar
• Fujino M, Yoshida N, Kimura K, Zhou J, Motegi Y, Komase K, Nakayama T. Development of a new neutralization test for measles virus. J Virol Meth. 2007;142:15–20. doi:10.1016/j.jviromet.2007.01.001.
   PubMed Web of Science ®Google Scholar
• Okafuji T, Okafuji T, Nakayama T. Persistence of immunity acquired after a single dose of rubella vaccine in Japan. Jpn J Infect Dis. 2016;69:221–23. doi:10.7883/yoken.JJID.2015.162.
   PubMed Web of Science ®Google Scholar
• Matsubara K, Iwata S, Nakayama T. Antibodies against mumps virus component proteins. J Infect Chemother. 2012;18(4):466–71. doi:10.1007/s10156-011-0358-3.
   PubMed Web of Science ®Google Scholar
• Pipkin PA, Afzal MA, Heath AB, Minor PD. Assay of humoral immunity to mumps virus. J Virol Methods. 1999;79(2):219–25. doi:10.1016/S0166-0934(99)00019-1.
   PubMed Web of Science ®Google Scholar